SEP-225289

SEP-225289
Systematic (IUPAC) name
	(1R)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
ATC code	?
PubChem	CID 9900576
Chemical data
Formula	C15H22ClN
Mol. mass	251.794 g/mol
SMILES	eMolecules & PubChem
(what is this?) (verify);

From Wikipedia, the free encyclopedia

(Redirected from SEP-225,289)

Jump to: navigation, search

SEP-225,289 is an antidepressant drug derived from the active enantiomer of sibutramine, which was being developed by Sepracor. It is a so-called triple reuptake inhibitor (TRI).^[1]^[2]

[edit] References

^ Chen Z, Skolnick P (September 2007). "Triple uptake inhibitors: therapeutic potential in depression and beyond". Expert Opin Investig Drugs 16 (9): 1365–77. doi:10.1517/13543784.16.9.1365. PMID 17714023.
^ DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, Kharidia J, Robertson B, Mann JJ, Parsey RV (July 2011). "SEP-225289 serotonin and dopamine transporter occupancy: a PET study". J. Nucl. Med. 52 (7): 1150–5. doi:10.2967/jnumed.110.084525. PMID 21680689.

US application 2007203111, Shao L, Wang F, Malcolm SC, Hewitt MC, Bush LR, Ma J, Varney MA, Campbell U, Engel SR, Hardy LW, Koch P, Campbell JE, "Cycloalkylamines as monoamine reuptake inhibitors", published 2007-08-30, assigned to Sepracor Inc.

US patent 7129378, Han X, Krishnamurthy D, Senanayake CH, Lu Z-H, "Method of preparing amine stereoisomers", published 2005-07-28, assigned to Apsinterm LLC

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.